TY - JOUR
T1 - The Preferential Use of Anakinra in Various Settings of FMF
T2 - A Review Applied to an Updated Treatment-Related Perspective of the Disease
AU - Giat, Eitan
AU - Ben-Zvi, Ilan
AU - Lidar, Merav
AU - Livneh, Avi
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Familial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory dis-ease, is manifested with recurrent and chronic inflammation and amyloid A (AA) amyloidosis, driven by overproduction of interleukin 1 (IL-1) through an activated pyrin inflammasome. Consequently, non-responsiveness to colchicine, the cornerstone of FMF treatment, is nowadays addressed by IL-1-blockers. Each of the two IL-1 blockers currently used in FMF, anakinra and canakinumab, has its own merits for FMF care. Here we focus on anakinra, a recombinant form of the naturally occurring IL-1 receptor antagonist, and explore the literature by using PubMed regarding the utility of anakinra in certain conditions of FMF. Occasionally we enrich published data with our own experience. To facilitate insights to anakinra role, the paper briefs some clinical, genetic, pathogenetic, and management aspects of FMF. The clinical settings of FMF covered in this review include colchicine resistance, AA amyloidosis, renal transplantation, protracted febrile myalgia, on-demand use, leg pain, arthritis, temporary suspension of colchicine, pediatric patients, and pregnancy and lactation. In many of these instances, either because of safety concerns or a necessity for only transient and short-term use, anakinra, due to its short half-life, is the preferred IL-1 blocker.
AB - Familial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory dis-ease, is manifested with recurrent and chronic inflammation and amyloid A (AA) amyloidosis, driven by overproduction of interleukin 1 (IL-1) through an activated pyrin inflammasome. Consequently, non-responsiveness to colchicine, the cornerstone of FMF treatment, is nowadays addressed by IL-1-blockers. Each of the two IL-1 blockers currently used in FMF, anakinra and canakinumab, has its own merits for FMF care. Here we focus on anakinra, a recombinant form of the naturally occurring IL-1 receptor antagonist, and explore the literature by using PubMed regarding the utility of anakinra in certain conditions of FMF. Occasionally we enrich published data with our own experience. To facilitate insights to anakinra role, the paper briefs some clinical, genetic, pathogenetic, and management aspects of FMF. The clinical settings of FMF covered in this review include colchicine resistance, AA amyloidosis, renal transplantation, protracted febrile myalgia, on-demand use, leg pain, arthritis, temporary suspension of colchicine, pediatric patients, and pregnancy and lactation. In many of these instances, either because of safety concerns or a necessity for only transient and short-term use, anakinra, due to its short half-life, is the preferred IL-1 blocker.
KW - AA amyloidosis
KW - anakinra
KW - chronic renal failure
KW - colchicine failure
KW - exertional leg pain
KW - familial Mediterranean fever (FMF)
KW - interleukin 1 blockers
KW - kidney transplantation
KW - protracted febrile myalgia
KW - safety
UR - http://www.scopus.com/inward/record.url?scp=85127424679&partnerID=8YFLogxK
U2 - 10.3390/ijms23073956
DO - 10.3390/ijms23073956
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 35409316
AN - SCOPUS:85127424679
SN - 1661-6596
VL - 23
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 7
M1 - 3956
ER -